Compare Ginkgo Bioworks Holdings Inc (DNA) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs iShares MSCI China ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.78 (market cap $763.64M), while iShares MSCI China ETF trades at $52.09 (market cap $5.94B). The key difference: iShares MSCI China ETF is far larger — about 7.8× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and iShares MSCI China ETF for 63 Days on average.
| DNA | MCHI | |
|---|---|---|
Market Cap | $763.64M | $5.94B |
Volume | 3,204,177 | 1,575,471 |
Sector | Health | Broad Market / Factor |
52-Week High | $15.83 | $65.59 |
52-Week Low | $5.48 | $50.48 |
Typical Hold Time | 7 Days | 63 Days |
Enterprise Value | $865.59M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.
The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.
MCHI, the iShares MSCI China ETF, trades at $51.64, down 1.11% with a bearish technical outlook. The ETF faces pressure from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent news highlights mixed signals with strong corporate profit growth but concerns about export controls and trade tensions. Technical indicators show strong bearish momentum with moving averages signaling sell pressure while oscillators remain neutral.
The outlook remains cautious given China's macroeconomic headwinds and trade uncertainties. Investment opportunity exists in MCHI's significant discount to historical valuations compared to US indices, but risks include potential export restrictions, protectionism threats, and ongoing economic rebalancing challenges that could pressure Chinese equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
